AA
CATX icon

Auctus Advisors’s Perspective Therapeutics CATX Stock Holding History

Auctus Advisors’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.4K Buy
20,344
+4,796
+31% +$18.1K 0.06% 34
2026
Q1 		$64.8K Sell
15,548
-16,125
-51% -$68.1K 0.06% 29
2025
Q4 		$87.1K Buy
+31,673
New +$90.4K 0.08% 26

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Auctus Advisors's CATX Position: Q2 2026 in Review

Auctus Advisors increased its Perspective Therapeutics (CATX) stake by 31% in Q2 2026, buying an estimated $18.1K and bringing the position to 20,344 shares worth $69.4K. The position accounts for 0.06% of the portfolio, ranked #34.

Auctus Advisors first reported a position in CATX in Q4 2025 and has held it in 3 quarters since. The position peaked at $87.1K in Q4 2025. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Auctus Advisors held 20,344 shares of Perspective Therapeutics worth $69.4K as of Q2 2026.
  • Auctus Advisors bought 4,796 Perspective Therapeutics shares in Q2 2026, an estimated $18.1K.
  • Perspective Therapeutics made up 0.06% of Auctus Advisors's portfolio in Q2 2026, its #34 holding.
  • Auctus Advisors first reported a position in Perspective Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Auctus Advisors's Perspective Therapeutics position peaked at $87.1K in Q4 2025.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Auctus Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.